ARCA BIOPHARMA ANNOUNCES AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19 ASSOCIATED COAGULOPATHY
arcabio.com/arca-bio...ciated-coagulopathy/
The Westminster, Colorado-based company said it plans to evaluate AB201, a selective inhibitor of tissue factor, as a potential treatment for COVID-19-associated coagulopathy and the related inflammatory response.
Coagulopathy is among the most serious adverse effects seen in COVID-19 patients, according to Arca.
The company said its AB201 has been previously tested through Phase 2 trials in more than 700 patients for other indications and has generated substantial safety data.
A Phase 2b/3 protocol is being developed in collaboration with the Colorado Prevention Center, the research wing of the University of Colorado, for hospitalized COVID-19 patients with elevated D-dimer levels, the company said.
www.benzinga.com/gen...00-on-covid-19-plans
www.globenewswire.co...ed-Coagulopathy.html
arcabio.com/arca-bio...ciated-coagulopathy/
The Westminster, Colorado-based company said it plans to evaluate AB201, a selective inhibitor of tissue factor, as a potential treatment for COVID-19-associated coagulopathy and the related inflammatory response.
Coagulopathy is among the most serious adverse effects seen in COVID-19 patients, according to Arca.
The company said its AB201 has been previously tested through Phase 2 trials in more than 700 patients for other indications and has generated substantial safety data.
A Phase 2b/3 protocol is being developed in collaboration with the Colorado Prevention Center, the research wing of the University of Colorado, for hospitalized COVID-19 patients with elevated D-dimer levels, the company said.
www.benzinga.com/gen...00-on-covid-19-plans
www.globenewswire.co...ed-Coagulopathy.html